Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161379 · ClinicalTrials.gov registry record · Phase 2
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03161379 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 31 participants.
The verdict
NCT03161379, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Nivolumab
- DRUG GVAX Pancreas Vaccine
- RADIATION Stereotactic Body Radiation (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03161379
The ClinicalTrials.gov registry entry for NCT03161379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03161379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03161379 about?
NCT03161379 is a clinical study titled "GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer". The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.
What is the current status of trial NCT03161379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-02-02. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT03161379?
The interventions under investigation include: Cyclophosphamide (DRUG), Nivolumab (DRUG), GVAX Pancreas Vaccine (DRUG), Stereotactic Body Radiation (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT03161379?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.